Evidence Based Digoxin Therapeutic Monitoring - A Lower and Narrower Therapeutic Range
作者: Amine BENLMOUDENEliane BILLAUD
作者单位: 1Paris. benlmoudenamine@gmail.com
刊名: International Journal of Medicine and Surgery, 2016, Vol.3 (1), pp.23-26
来源数据库: Mediterranean BioMedical Journals
DOI: 10.15342/ijms.v3i1.87
原始语种摘要: Cardiac glycosides have been used for congestive heart failure and certain cardiac arrhythmias for more than 200 years. Despite the introduction of a variety of new classes of drugs for the management of heart failure, specifically angiotensin-converting enzyme (ACE) inhibitors, b-adrenergic antagonists (bblockers), and the aldosterone antagonist spironolactone, digoxin continues to have an important role in long-term outpatient management. However, a narrow margin exists between therapeutic and toxic doses of digoxin, resulting in a high incidence of digoxin toxicity in clinical practice.A wide variety of placebo-controlled clinical trials have unequivocally shown that treatment with digoxin can improve symptoms, quality of life, and exercise tolerance in patients with mild, moderate, or...
全文获取路径: 地中海生物医学期刊 
分享到:

×
关键词翻译
关键词翻译
  • digoxin 地谷新
  • spironolactone 螺甾内酯
  • congestive 充血的
  • therapeutic 治疗的
  • converting 转换
  • outpatient 门诊病人
  • failure 破坏
  • heart 心脏
  • toxicity 毒性
  • exercise 练习